Development of lecithinized superoxide dismutase as a drug for IPF

Tohru Mizushima

研究成果: Article査読

1 被引用数 (Scopus)

抄録

Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.

本文言語English
ページ(範囲)69-76
ページ数8
ジャーナルYakugaku Zasshi
134
1
DOI
出版ステータスPublished - 2014
外部発表はい

ASJC Scopus subject areas

  • 薬理学
  • 薬科学

フィンガープリント

「Development of lecithinized superoxide dismutase as a drug for IPF」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル